Go All-In On Actavi...
Health Care: Drugs
Actavis Inc (ACT: NYSE)
$125.67 0.73 | 0.58%
06/18/13 - 04:00 PM ET
Latest Dividend:0.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:12/31/69
Price Earnings Ratio:n/a
Price Earnings Comparisons:
| ACT | Sector Avg. | S&P 500 |
|---|---|---|
| n/a | 0.00 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| 36.41 | 81.02 | 182.29 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | 29.00 | 1.12 | 0.28 |
| Net Income | -62.30 | -0.56 | -0.24 |
| EPS | -63.10 | -0.64 | -0.28 |
Earnings for ACT:
| EBITDA | 1.09B |
| REVENUE | 5.91B |
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $1.99 | $2.07 | $8.26 | $9.51 |
| Number of Analysts | 12 | 12 | 15 | 13 |
| High Estimate | $2.07 | $2.19 | $8.50 | $13.00 |
| Low Estimate | $1.92 | $1.87 | $8.02 | $8.40 |
| Prior Year | $1.42 | $1.35 | $6.00 | $8.26 |
| Growth Rate (Year over Year) | 40.20% | 53.27% | 37.72% | 15.14% |
Portfolios with ACT
- Portfolio NameUser Type
- ContributorHigh Volume Technicals for ...
- ContributorHigh Volume Technicals for ...
Latest ACT Headlines from TheStreet
- Actavis Reaches New 52-Week High (ACT) 04.19.13 | 04:04 pm
- Actavis Inc (ACT): Drugs' Featured Winner Of The Day 04.05.13 | 05:04 pm
- Actavis Inc Stock Upgraded (ACT) 04.03.13 | 05:04 am
- Stocks to Watch: Nasdaq OMX, Goldman, Ford, GM 04.02.13 | 05:04 am
- Actavis Stock Hits New 52-Week High (ACT) 04.01.13 | 09:04 am
- 5 Huge Stocks to Trade for Gains This Week 03.14.13 | 10:03 am
- Actavis Reaches New 52-Week High (ACT) 03.13.13 | 01:03 pm
- Actavis Inc (ACT): Today's Featured Health Care Winner 02.26.13 | 05:02 pm
- 5 Big Stock Trades Signaling 'Buy' 02.14.13 | 11:02 am
- Cramer's 'Mad Money' Recap: Coaling a Bottom 10.07.05 | 07:10 pm
Press Releases for ACT
- Actavis Reaches Agreements With Valeant To Launch Generic Versions Of Ziana® And Zyclara® - PR Newswire 04.10.13 | 08:04 am
- Actavis Reaches Agreements With Valeant To Launch Generic Versions Of Ziana® And Zyclara® - PR Newswire 04.10.13 | 08:04 am
- Actavis And Valeant Announce Actavis As Exclusive Authorized Generic Marketer Of Zovirax® Ointment; Co-Promotion Agreements On Zovirax® Cream And Cordran® Tape - PR Newswire 04.05.13 | 08:04 am
- Actavis And Valeant Announce Actavis As Exclusive Authorized Generic Marketer Of Zovirax® Ointment; Co-Promotion Agreements On Zovirax® Cream And Cordran® Tape - PR Newswire 04.05.13 | 08:04 am
- Actavis Confirms Court Issues TRO Related To Generic Pulmicort RESPULES® Distribution - PR Newswire 04.03.13 | 06:04 am
- Actavis Confirms Generic Fortesta® Patent Challenge - PR Newswire 03.01.13 | 09:03 am
- Actavis' Generic Suboxone® Receives FDA Approval - PR Newswire 02.25.13 | 07:02 am
- Actavis Reaches Settlement With Mallinckrodt Over Exalgo® 32 Mg Dosage Strength - PR Newswire 02.14.13 | 09:02 am
- Actavis, Inc. To Host Fourth Quarter 2012 Earnings Conference Call And Webcast - PR Newswire 02.01.13 | 09:02 am
Partner Headlines for ACT
- AstraZeneca loses US drug patent judgment - Financial Times 04.02.13 | 10:04 am
- Aetna Offloads Business and 4 Stocks At 52-Week Highs - Wall St. Cheat Sheet 04.02.13 | 09:04 am
- 4 Healthcare Stock Stories for Monday Investment Wellness - Wall St. Cheat Sheet 04.01.13 | 02:04 am
- 4 Healthcare Stock Stories for Monday Investment Wellness - Wall St. Cheat Sheet 04.01.13 | 02:04 am
- 'Pay For Delay' Case Could Change Generic Drug Rules - Investor's Business Daily 03.26.13 | 04:03 pm
